行情

GERN

GERN

杰龙
NASDAQ

实时行情|Nasdaq Last Sale

1.650
-0.045
-2.65%
盘后: 1.670 +0.02 +1.21% 18:38 01/15 EST
开盘
1.730
昨收
1.695
最高
1.740
最低
1.635
成交量
187.50万
成交额
--
52周最高
2.400
52周最低
0.7500
市值
5.12亿
市盈率(TTM)
-4.6637
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
Geron宣布在难治性骨髓纤维化中启动IMpactMF 3期临床试验
Geron Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening
Benzinga · 2020/12/11 13:31
Geron宣布IMerge 3期临床试验在低风险MDS中的注册里程碑为50%
Geron Announces Fifty Percent Enrollment Milestone in IMerge Phase 3 Clinical Trial in Lower Risk MDS IMerge Phase 3 enrollment completion expected in second quarter of 2021 Top-line results expected in
Benzinga · 2020/12/10 13:36
Recap: Geron Q3 Earnings
Benzinga · 2020/11/05 21:25
Recap: Geron Q3 Earnings
Shares of Geron (NASDAQ:GERN) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share increased 25.00% over the past year to ($0.06), which were in line with the estimate of ($0.06).Revenue of $108,000 decreased by 17.56% year over year, which beat the estimate of $40,000.Guidance Geron hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Nov 05, 2020View more earnings on GERNTime: 04:30 PMET Webcast URL: http://www.directeventreg.com/registration/event/7879966Recent Stock Performance 52-week high: $2.40Company's 52-week low was at $0.75Price action over last quarter: Up 10.71%Company Description Geron Corp is a clinical stage biopharmaceutical company focused on research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses the global rights to this drug.See more from Benzinga * Click here for options trades from Benzinga * Recap: Trade Desk Q3 Earnings * 12 Technology Stocks Moving In Thursday's Intraday Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 2020/11/05 21:25
Geron Announces Publication Of IMerge Phase 2 Data In Journal Of Clinical Oncology
Results support ongoing IMerge Phase 3 clinical trial Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published in
Benzinga · 2020/10/28 21:03
Is Geron Corporation (NASDAQ:GERN) Popular Amongst Institutions?
finviz · 2020/10/23 13:03
Is Geron Corporation (NASDAQ:GERN) Popular Amongst Institutions?
finviz · 2020/10/23 13:03
物联网科技货运服务商G7宣布5年投放10万台智能挂车
界面 · 2020/10/22 05:01
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解GERN最新的财务预测,通过GERN每股收益,每股净资产,每股现金流等数据分析杰龙近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测GERN价格均价为4.000,最高价位7.00,最低价为3.000。
EPS
机构持股
总机构数: 208
机构持股: 1.75亿
持股比例: 56.28%
总股本: 3.10亿
类型机构数股数
增持
56
1,912.95万
建仓
39
1,480.88万
减持
23
1,793.16万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.34%
制药与医学研究
+0.21%
高管信息
Chairman/President/Chief Executive Officer/Director
John Scarlett
Chief Financial Officer/Executive Vice President - Finance/Treasurer
Olivia Bloom
Chief Operating Officer/Executive Vice President
Andrew Grethlein
Executive Vice President/Secretary
Stephen Rosenfield
Vice President
Israel Gutierrez
Executive Vice President
Anil Kapur
Executive Vice President
Melissa Kelly Behrs
Executive Vice President
Aleksandra Rizo
Lead Director/Independent Director
Karin Eastham
Vice President/Director of Human Resources
Shannon Odam
Independent Director
Dawn Bir
Vice President
Sharo McBain
Independent Director
V. Bryan Lawlis
Vice President - Business Development
Lynn Bodarky
Independent Director
Susan Molineaux
Independent Director
Elizabeth O'Farrell
Independent Director
Robert Spiegel
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
GERN 简况
Geron Corp(Geron)是一家后期临床生物制药公司,专注于imetelstat(血液性骨髓恶性肿瘤的治疗药物)的开发和商业化。该公司运营一个业务部门,该部门从事肿瘤治疗产品的开发业务。imetelstat是一种脂质共轭13-mer寡核苷酸,旨在与端粒酶的核糖核酸(RNA)模板互补并以高亲和力结合,从而直接抑制端粒酶活性。imetelstat的临床研究包括IMerge(低风险骨髓增生异常综合症(MDS)的II/III期试验)和IMbark(中度II或高危骨髓纤维化的II期试验)。
展开
热门股票
代码
价格
涨跌幅

微牛提供Geron Corporation(NASDAQ-GERN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的GERN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易GERN股票基本功能。